Compare Build A Bear Workshop Inc (BBW) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Biogen Inc — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $461.88M), while Biogen Inc trades at $203.5 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 65.2× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BBW | BIIB | |
|---|---|---|
Market Cap | $461.88M | $30.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $216.63 |
52-Week Low | $29.84 | $128.93 |
Enterprise Value | $561.32M | $37.20B |
Dividend Yield | 2.5% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
